Commonalities between the pro-fibrotic mechanisms in COPD and IPF

Pulmonary Pharmacology and Therapeutics

Volumn 25, Issue 4, 2012, Pages 276-280

  Murray, Lynne A ^a  

^a MEDIMMUNE   (United States)

Author keywords

Chemokine; Chitinase; EMT; Fibrocyte; Fibrosis; Macrophage; Remodelling

Indexed keywords

CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR7; COLLAGEN TYPE 1; EPIDERMAL GROWTH FACTOR; FIBRONECTIN; MATRIX METALLOPROTEINASE;

ARTICLE; CELL ACTIVATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; DISEASE ASSOCIATION; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; FIBROSING ALVEOLITIS; GASTROESOPHAGEAL REFLUX; HUMAN; LUNG CANCER; MACROPHAGE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; SMOKING;

AIRWAY REMODELING; CHEMOKINES; CHITINASE; EXTRACELLULAR MATRIX; FIBROBLASTS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MACROPHAGES, ALVEOLAR; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84864063004     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2011.08.003     Document Type: Article

References (76)

1. Hogg J.C., et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004, 350(26):2645-2653.
2. Gosselink J.V., et al. Differential expression of tissue repair genes in the pathogenesis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010, 181(12):1329-1335.
3. Hogg J.C., et al. What drives the peripheral lung-remodeling process in chronic obstructive pulmonary disease?. Proc Am Thorac Soc 2009, 6(8):668-672.
4. Hogg J. Peripheral lung remodelling in asthma and chronic obstructive pulmonary disease. Eur Respir J 2004, 24(6):893-894.
5. Raghu G., et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183(6):788-824.
6. Gross T.J., Hunninghake G.W. Idiopathic pulmonary fibrosis. N Engl J Med 2001, 345(7):517-525.
7. Moeller A., et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009, 179(7):588-594.
8. Prasse A., et al. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum 2007, 56(5):1685-1693.
9. Hurst J.R., et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010, 363(12):1128-1138.
10. Raghu G., et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 2006, 27(1):136-142.
11. Sandler R.S., et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002, 122(5):1500-1511.
12. Johnson D.A., Fennerty M.B. Heartburn severity underestimates erosive esophagitis severity in elderly patients with gastroesophageal reflux disease. Gastroenterology 2004, 126(3):660-664.
13. Bisaccioni C., et al. Comorbidities in severe asthma: frequency of rhinitis, nasal polyposis, gastroesophageal reflux disease, vocal cord dysfunction and bronchiectasis. Clin (Sao Paulo) 2009, 64(8):769-773.
14. Thiery J.P. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003, 15(6):740-746.
15. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J Clin Invest 2009, 119(6):1420-1428.
16. Dasari V., et al. Epithelial-mesenchymal transition in lung cancer: is tobacco the "smoking gun"?. Am J Respir Cell Mol Biol 2006, 35(1):3-9.
17. Willis B.C., Borok Z. TGF-{beta}-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol 2007.
18. Valcourt U., et al. TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol Biol Cell 2005, 16(4):1987-2002.
19. Zavadil J., Bottinger E.P. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005, 24(37):5764-5774.
20. Zavadil J., et al. Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. Embo J 2004, 23(5):1155-1165.
21. Borok Z., et al. Modulation of t1alpha expression with alveolar epithelial cell phenotype in vitro. Am J Physiol 1998, 275(1 Pt 1):L155-L164.
22. Danto S.I., et al. Reversible transdifferentiation of alveolar epithelial cells. Am J Respir Cell Mol Biol 1995, 12(5):497-502.
23. Torday J.S., Torres E., Rehan V.K. The role of fibroblast transdifferentiation in lung epithelial cell proliferation, differentiation, and repair in vitro. Pediatr Pathol Mol Med 2003, 22(3):189-207.
24. Kim K.K., et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA 2006, 103(35):13180-13185.
25. Kalluri R., Neilson E.G. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003, 112(12):1776-1784.
26. Selgas R., Jimenez-Heffernan J., Lopez-Cabrera M. On the epithelial-mesenchymal transition of mesothelial cells. Kidney Int 2004, 66(2):866-867. author reply 867.
27. Grunert S., Jechlinger M., Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 2003, 4(8):657-665.
28. Iwano M., et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002, 110(3):341-350.
29. Okada H., et al. Early role of Fsp1 in epithelial-mesenchymal transformation. Am J Physiol 1997, 273(4 Pt 2):F563-F574.
30. Saika S., et al. Smad3 signaling is Required for epithelial-mesenchymal transition of Lens epithelium after injury. Am J Pathol 2004, 164(2):651-663.
31. Kasai H., et al. TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res 2005, 6:56.
32. Willis B.C., et al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol 2005, 166(5):1321-1332.
33. Youlden D.R., Cramb S.M., Baade P.D. The International Epidemiology of Lung Cancer: geographical distribution and secular trends. J Thorac Oncol 2008, 3(8):819-831.
34. Proctor R.N. Tobacco and the global lung cancer epidemic. Nat Rev Cancer 2001, 1(1):82-86.
35. Cosio M.G., Saetta M., Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009, 360(23):2445-2454.
36. Walser T., et al. Smoking and lung cancer: the role of inflammation. Proc Am Thorac Soc 2008, 5(8):811-815.
37. Lama V.N., Phan S.H. The extrapulmonary origin of fibroblasts: stem/progenitor cells and beyond. Proc Am Thorac Soc 2006, 3(4):373-376.
38. Shao D.D., et al. Pivotal Advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation. J Leukoc Biol 2008, 83(6):1323-1333.
39. Abe R., et al. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol 2001, 166(12):7556-7562.
40. Bucala R., et al. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1994, 1(1):71-81.
41. Chesney J., et al. Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J Immunol 1998, 160(1):419-425.
42. Schmidt M., et al. Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J Immunol 2003, 171(1):380-389.
43. Abe S., et al. Cells derived from the circulation contribute to the repair of lung injury. Am J Respir Crit Care Med 2004, 170(11):1158-1163.
44. Moore B.B., et al. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol 2005, 166(3):675-684.
45. Moore B.B., et al. The role of CCL12 in the recruitment of fibrocytes and lung fibrosis. Am J Respir Cell Mol Biol 2006, 35(2):175-181.
46. Hashimoto N., et al. Bone marrow-derived progenitor cells in pulmonary fibrosis. J Clin Invest 2004, 113(2):243-252.
47. Phillips R.J., et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 2004, 114(3):438-446.
48. Murray L.A., et al. Hyper-responsiveness of IPF/UIP fibroblasts: interplay between TGFbeta1, IL-13 and CCL2. Int J Biochem Cell Biol 2008, 40(10):2174-2182.
49. Weislander E., et al. Increased circulating levels of fibroscytes in COPD - a sign of ongoing lung repair?. Am J Respir Crit Care Med 2010, 179:A1992.
50. Hancock A., et al. Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol 1998, 18(1):60-65.
51. Zhou Y., et al. Alterations in adenosine metabolism and signaling in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. PLoS One 2010, 5(2):e9224.
52. Barnes P.J. Alveolar macrophages as orchestrators of COPD. Copd 2004, 1(1):59-70.
53. Savill J. Apoptosis in resolution of inflammation. J Leukoc Biol 1997, 61(4):375-380.
54. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003, 3(1):23-35.
55. Tiemessen M.M., et al. CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci USA 2007, 104(49):19446-19451.
56. Murray L.A., et al. Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. PLoS One 2010, 5(3):e9683.
57. Mathai S.K., et al. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Lab Invest 2010, 90(6):812-823.
58. Hodge S., et al. Cigarette smoke-induced changes to alveolar macrophage phenotype and function is Improved by Treatment with Procysteine. Am J Respir Cell Mol Biol 2010.
59. Shaykhiev R., et al. Smoking-dependent reprogramming of alveolar macrophage polarization: implication for pathogenesis of chronic obstructive pulmonary disease. J Immunol 2009, 183(4):2867-2883.
60. Pilling D., et al. Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. J Immunol 2007, 179(6):4035-4044.
61. Murray L.A., et al. TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P. Int J Biochem Cell Biol 2010, 43(1):154-162.
62. Prasse A., et al. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med 2006, 173(7):781-792.
63. Lee C.G., et al. Role of chitin, Chitinase/Chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol 2010.
64. Lee C.G., et al. Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med 2009, 206(5):1149-1166.
65. Chupp G.L., et al. A chitinase-like protein in the lung and circulation of patients with severe asthma. N Engl J Med 2007, 357(20):2016-2027.
66. Letuve S., et al. Lung chitinolytic activity and chitotriosidase are elevated in chronic obstructive pulmonary disease and contribute to lung inflammation. Am J Pathol 2009, 176(2):638-649.
67. Matsuura H., et al. Role of breast regression protein (BRP)-39 in the pathogenesis of cigarette smoke-induced inflammation and emphysema. Am J Respir Cell Mol Biol 2010.
68. Sohn M.H., et al. The chitinase-like proteins breast regression protein-39 and YKL-40 regulate hyperoxia-induced acute lung injury. Am J Respir Crit Care Med 2010, 182(7):918-928.
69. Korthagen N.M., et al. Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis. Respir Med 2011, 105(1):106-113.
70. Furuhashi K., et al. Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis. Respir Med 2010, 104(8):1204-1210.
71. Castano A.P., et al. Serum amyloid P inhibits fibrosis through Fc gamma R-dependent monocyte-macrophage regulation in vivo. Sci Transl Med 2009, 1(5):5ra13.
72. Haudek S.B., et al. Fc receptor engagement mediates differentiation of cardiac fibroblast precursor cells. Proc Natl Acad Sci U S A 2008, 105(29):10179-10184.
73. Murray L.A., et al. Serum amyloid P ameliorates radiation-induced oral mucositis and fibrosis. Fibrogenesis Tissue Repair 2010, 3:11.
74. Barry-Hamilton V., et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 2010, 16(9):1009-1017.
75. Horan G.S., et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med 2008, 177(1):56-65.
76. Hahm K., et al. Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse. Am J Pathol 2007, 170(1):110-125.